A Double Blind Placebo Controlled Study to Evaluate the Effect of Bexagliflozin Tablets on Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Bexagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Theracos
- 28 Feb 2018 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018.
- 27 Jan 2018 This trial has been completed in Spain (end date: 2018-01-11)
- 04 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.